These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 27832976)

  • 1. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly.
    Takada H; Hifumi T; Nishimoto N; Kanemura T; Yoshioka H; Okada I; Kiriu N; Inoue J; Koido Y; Kato H
    Am J Emerg Med; 2017 Feb; 35(2):245-248. PubMed ID: 27832976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.
    Niederman MS; Chastre J; Solem CT; Wan Y; Gao X; Myers DE; Haider S; Li JZ; Stephens JM
    Clin Ther; 2014 Sep; 36(9):1233-1243.e1. PubMed ID: 25066668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
    Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
    Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
    Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
    Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Pneumonia: Institutional Implications.
    Tong MC; Wisniewski CS; Wolf B; Bosso JA
    Pharmacotherapy; 2016 Jul; 36(7):731-9. PubMed ID: 27208687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective.
    Rello J; Nieto M; Solé-Violán J; Wan Y; Gao X; Solem CT; De Salas-Cansado M; Mesa F; Charbonneau C; Chastre J
    Med Intensiva; 2016 Nov; 40(8):474-482. PubMed ID: 27061776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
    Alaniz C; Pogue JM
    Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid Versus Vancomycin in the Empiric Treatment of Nosocomial Pneumonia: A Cost-Utility Analysis Incorporating Results from the ZEPHyR Trial.
    Collins CD; Schwemm AK
    Value Health; 2015 Jul; 18(5):614-21. PubMed ID: 26297089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of diabetes mellitus on outcomes of patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: data from a prospective double-blind clinical trial comparing treatment with linezolid versus vancomycin.
    Equils O; da Costa C; Wible M; Lipsky BA
    BMC Infect Dis; 2016 Sep; 16(1):476. PubMed ID: 27600290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation among Chinese patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus and treated with linezolid or vancomycin: a secondary, post-hoc analysis based on a Phase 4 clinical trial study.
    Wan Y; Li Q; Chen Y; Haider S; Liu S; Gao X
    J Med Econ; 2016; 19(1):53-62. PubMed ID: 26490296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Taiwan.
    Lin PC; Wang BC; Kim R; Magyar A; Lai CC; Yang YW; Huang YC
    J Microbiol Immunol Infect; 2016 Feb; 49(1):46-51. PubMed ID: 26454421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus in Japan: A multicenter prospective observational cohort study.
    Miyazaki T; Yanagihara K; Kakeya H; Izumikawa K; Mukae H; Shindo Y; Yamamoto Y; Tateda K; Tomono K; Ishida T; Hasegawa Y; Niki Y; Watanabe A; Soma K; Kohno S
    J Infect Chemother; 2020 Feb; 26(2):242-251. PubMed ID: 31575499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
    Caffrey AR; Morrill HJ; Puzniak LA; Laplante KL
    Pharmacotherapy; 2014 May; 34(5):473-80. PubMed ID: 24420846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia.
    Chavanet P
    Med Mal Infect; 2013 Dec; 43(11-12):451-5. PubMed ID: 24238896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
    Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
    Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
    De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
    Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of clinical success among a national Veterans Affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
    Caffrey AR; Morrill HJ; Puzniak LA; LaPlante KL
    Clin Ther; 2014 Apr; 36(4):552-9. PubMed ID: 24631473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 600 mg of fixed-dose linezolid in renally impaired patients versus 15 mg/kg intermittent dose-optimized vancomycin in renally non-impaired patients: A single centre retrospective analysis for adult patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus.
    Wang M; Liu X; Tian Z
    Trop Med Int Health; 2023 Apr; 28(4):315-323. PubMed ID: 36852899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus.
    Wunderink RG; Mendelson MH; Somero MS; Fabian TC; May AK; Bhattacharyya H; Leeper KV; Solomkin JS
    Chest; 2008 Dec; 134(6):1200-1207. PubMed ID: 18719064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.